NCT05633927View on ClinicalTrials.gov

Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed

CompletedOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

December 1, 2022

Conditions
SARS-CoV-2 RNA VaccinesHIV Infection
Interventions
BIOLOGICAL

SARS-CoV-2 Vaccine

Analyse humoral and cellular response to SARS-CoV-2 Vaccine.

Trial Locations (1)

41013

Virgen del Rocio University Hospital, Seville

All Listed Sponsors
lead

Hospitales Universitarios Virgen del Rocío

OTHER

NCT05633927 - Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed | Biotech Hunter | Biotech Hunter